Loading clinical trials...
Loading clinical trials...
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of HSK21542 Injection in Subjects Undergoing Hemodialysis
Conditions
Interventions
Stage I:HSK21542 0.05 μg/kg
Stage I:HSK21542 0.15 μg/kg
+4 more
Locations
1
China
Guizhou Medical University Affiliated Hospital
Guiyang, Guizhou, China
Start Date
August 10, 2020
Primary Completion Date
October 28, 2021
Completion Date
October 28, 2021
Last Updated
August 9, 2022
NCT02143648
NCT05575193
NCT03422653
NCT01660243
NCT03998163
NCT00494975
Lead Sponsor
Haisco Pharmaceutical Group Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions